MedPath

Clinical Trial News

Saniona Advances Neurological Pipeline with Strategic Partnerships and Strong Financial Position

  • Saniona secured SEK 115 million through warrant exercise and maintains SEK 261 million in cash, strengthening its financial runway to advance three internal neurological programs to Phase 2 trials.
  • The company's partnership with Acadia Pharmaceuticals includes $28 million upfront and potential $582 million in milestone payments, with SAN711 advancing toward Phase 2 for essential tremor in 2026.
  • Strategic collaborations with Boehringer Ingelheim and Cephagenix joint venture validate Saniona's ion channel platform, while partner Medix pursues tesofensine approval in Mexico for obesity treatment.
  • Saniona expects to finalize regulatory packages for SAN2355 by end-2025 and SAN2219 by first half of 2026, positioning multiple assets for clinical advancement.

Patent Settlements Accelerate Generic and Biosimilar Market Entry, Generating $423 Billion in Healthcare Savings

  • Patent settlements between brand-name and generic/biosimilar manufacturers have accelerated market entry by an average of 64 months before patent expiration, generating $423 billion in healthcare system savings since 2013.
  • Analysis of 288 molecules revealed that 84 had settlements enabling early market entry, with 17% of these launching more than a decade before patent expiry and averaging $5 billion in savings per molecule.
  • The study highlights teriflunomide as a notable example, where a 2017 settlement enabled generic launch 11 years before patent expiry, saving the healthcare system an estimated $1.1 billion in 2023 alone.

Purple Biotech to Present Novel CAPTN-3 Tri-Specific Antibody Platform at EACR 2025

  • Purple Biotech will present its novel CAPTN-3 tri-specific antibody platform at the European Association for Cancer Research Annual Congress in Lisbon from June 16-19, 2025.
  • The CAPTN-3 platform features conditionally activated antibodies that engage both T cells and NK cells to induce localized immune responses within the tumor microenvironment.
  • IM1240, the first tri-specific antibody in development, targets the 5T4 antigen expressed in various solid tumors and associated with advanced disease and poor clinical outcomes.

Breast Cancer Trials Launches Remote Telehealth Pre-Screening to Expand Access for Regional Patients

  • Breast Cancer Trials (BCT) is implementing a remote telehealth pre-screening process to broaden clinical trial access for regional and remote patients with molecularly targeted cancer treatments.
  • The process focuses on trials requiring specific molecular characteristics, utilizing circulating tumor DNA (ctDNA) blood tests and tissue samples tested at central laboratories.
  • Patients undergo telehealth consultations with BCT's Central Investigator for trial explanation and consent, with samples tested for trial-specific molecular targets before eligibility determination.
  • The initiative aims to improve trial participant diversity, enhance cancer outcomes, and strengthen research capacity while being piloted with the OLIO clinical trial.

Traws Pharma Stock Surges 94% Following Breakthrough Drug Trial Success

  • Traws Pharma Inc. (NASDAQ: TRAW) experienced a dramatic stock surge of up to 93.66% on June 3, 2025, driven by breakthrough drug trial success that significantly boosted investor confidence.
  • The company reported strong financial performance with net income of $21.49 million by March 31, 2025, and earnings per share of $2.17, despite modest revenue of $57,000.
  • Strategic partnerships and successful trials in novel therapeutic segments have positioned the company for potential growth in untapped pharmaceutical markets.
  • Market analysts view the surge as potentially significant for the biotechnology sector, though they emphasize the need for continued observation given the volatile nature of pharmaceutical stocks.

AI-Guided Drug Discovery Identifies Promising Cancer Treatment Combinations Using Existing Non-Cancer Medications

AIDrug Discovery
  • University of Cambridge researchers used GPT-4 to identify drug combinations that could treat cancer, finding that three of 12 AI-suggested combinations outperformed current breast cancer drugs in laboratory tests.
  • The study represents the first closed-loop system where experimental results guided an AI language model, which then suggested further drug combinations for testing by human scientists.
  • Promising combinations include simvastatin (cholesterol medication) and disulfiram (alcohol dependence treatment), demonstrating potential for therapeutic repurposing of existing approved drugs.
  • This collaborative approach between AI and human scientists offers a scalable method for drug discovery that could reduce costs and accelerate the identification of new cancer treatments.

Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial

Monoclonal Antibody
  • A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.
  • The combination therapy increased median progression-free survival by 3.9 months to 11 months total, with a 30% reduction in disease progression and death risk compared to the current standard treatment.
  • Results from the Phase III CAMPASS study involving over 500 patients were presented at the American Society of Clinical Oncology annual meeting as a Late-Breaking Abstract.
  • The achievement marks a potential shift from Chinese pharmaceutical companies being followers to leaders in international cancer treatment development.

Fujirebio Launches Automated sTREM2 Assay to Advance Neuroinflammation Research in Alzheimer's Disease

  • Fujirebio has launched the Lumipulse G sTREM2 assay, a fully automated test that measures soluble TREM2 biomarkers in cerebrospinal fluid and blood within 35 minutes for research purposes.
  • The sTREM2 biomarker provides insights into microglial activation and neuroinflammation associated with Alzheimer's disease and other neurodegenerative conditions.
  • This new assay complements Fujirebio's existing neurological biomarker portfolio including GFAP, NfL, and pTau, offering researchers a more comprehensive view of disease mechanisms on a single platform.

BioInvent Advances BI-1910 Anti-TNFR2 Antibody with Population Modeling Data at PAGE 2025

Monoclonal Antibody
  • BioInvent successfully developed a population model to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad dose range, supporting optimal dose selection for upcoming Phase 2a studies.
  • The anti-TNFR2 agonist antibody demonstrated stable disease in six out of 12 evaluable patients during Phase 1 dose escalation, with favorable pharmacokinetics and robust target engagement inducing T cell proliferation.
  • Phase 2a studies of BI-1910 as both single agent and in combination with pembrolizumab are planned to initiate in the second half of 2025, targeting hepatocellular cancer and other solid tumors.

Caltech's Smart Bandage Technology Demonstrates Early Biomarker Detection in First Human Clinical Trial

  • California Institute of Technology researchers successfully transitioned their iCares smart bandage system from animal models to human clinical testing, enrolling 20 patients with diabetic foot ulcers and venous leg wounds.
  • The smart bandage demonstrated the ability to detect critical biomarkers including nitric oxide, hydrogen peroxide, and oxygen levels one to three days before patients experienced clinical symptoms.
  • The device's machine learning algorithm successfully classified wound severity and healing potential with accuracy comparable to experienced clinicians, providing objective wound assessment capabilities.
  • The technology represents a significant advancement over traditional wound monitoring methods by enabling real-time continuous monitoring of wound biomarkers through an innovative microfluidic system.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.